Cronos (CRON) Income towards Parent Company (2019 - 2026)
Cronos' (CRON) quarterly Income towards Parent Company came in at $15.7 million in Q1 2026, up 103.43% year-on-year from $7.7 million in Q1 2025, and up 3299.8% quarter-over-quarter from -$491000.0 in Q4 2025.
Cronos (CRON) Income towards Parent Company (2019 - 2026) Analysis & Trends
Cronos' Income towards Parent Company history runs 7 years deep, the most recent figure standing at $15.7 million for Q1 2026.
- On a quarterly basis, Income towards Parent Company rose 103.43% year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $5.1 million, a 34.49% decrease from a year earlier, with the FY2023 full-year figure at -$4.1 million, up 69.65% from the prior year.
- Income towards Parent Company improved to $15.7 million in Q1 2026 per CRON's latest filing, from -$491000.0 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $28.3 million in Q3 2025 and bottomed at -$38.5 million in Q2 2025.
- The 4-year median for Income towards Parent Company is -$856500.0 (2023), against an average of -$50000.0.
- Across the five-year window, Income towards Parent Company sank 4710.98% in 2022 and surged 104.63% in 2023, its largest moves.
- Year by year, Income towards Parent Company stood at -$2.7 million in 2022, then surged by 104.63% to $124000.0 in 2023, then slumped by 495.97% to -$491000.0 in 2025, then surged by 3299.8% to $15.7 million in 2026.
- Per Business Quant, the three latest CRON Income towards Parent Company figures stand at $15.7 million (Q1 2026), -$491000.0 (Q4 2025), and $28.3 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.69 Bn | 87.82 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.57 Bn | 30.63 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.08 Bn | 20.93 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.43 Bn | 22.43 Bn | - |
| 7 | Viatris | 20.23 Bn | 18.42 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Cronos | 1.08 Bn | 257.46 Mn | 19.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.71 Mn |
| Dec 31, 2025 | -491,000.00 |
| Sep 30, 2025 | 28.32 Mn |
| Jun 30, 2025 | -38.48 Mn |
| Mar 31, 2025 | 7.72 Mn |
| Dec 31, 2023 | 124,000.00 |
| Sep 30, 2023 | -182,000.00 |
| Jun 30, 2023 | -2.83 Mn |
| Mar 31, 2023 | -1.22 Mn |
| Dec 31, 2022 | -2.68 Mn |
| Sep 30, 2022 | -3.78 Mn |
| Jun 30, 2022 | -2.81 Mn |
| Dec 31, 2021 | -268.63 Mn |
| Sep 30, 2021 | 82,000.00 |
| Jun 30, 2021 | -561,000.00 |
| Mar 31, 2021 | -21,000.00 |
| Dec 31, 2020 | -131,000.00 |
| Sep 30, 2020 | -473,000.00 |
| Jun 30, 2020 | -46,000.00 |
| Dec 31, 2019 | -300,000.00 |